Search Results

Emmaus Life Sciences, Inc. today announced the signing of an agreement with Kainos Medicine, Inc.

MDimune Inc. and Kainos Medicine, Inc., has inked a collaboration pact and possible licensing deal with MDimune Inc. for disruptive cancer therapy development based on cell-derived vesicles (CDVs) like extracellular vesicles (EVs) loaded with Fas-associated Factor 1 (FAF1) expressing mRNA or protein.

Jefferies analyst Kelly Shi in a Sunday note to investors said that both data drops for Revolution Medicines’ experimental RAS inhibitors are positive and could be “synergistic” in the first-line setting for pancreatic ductal adenocarcinoma.

Looking to build on the success of Chinook Therapeutics, founded by Versant in 2019 and acquired by Novartis last year, the companies on Thursday launched Borealis Biosciences with $150 million in funding to develop RNA therapeutics for kidney diseases.

Emmaus Life Sciences, Inc. (OTC: EMMA) , a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, announced today that it has entered into an agreement with Kainos Medicine, Inc. (“Kainos”) to lead the preclinical development of Kainos’ patented IRAK4 inhibitor (KM10544) as an anti-cancer drug

In an effort to expand its cash runway beyond 12 months, Prime Medicine has signed a deal with Bristol Myers Squibb worth a potential $3.5 billion, while also streamlining its pipeline to trim costs.

Experts say the time is now to develop and provide widespread access to genetic medicines for the rarest diseases. What’s more, they say it is a moral imperative.